Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)Akira Inoue, T. Nukiwa, Kunihiko Kobayashi et al.|Annals of Oncology|2012Cited by 555
Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902Shunichi Sugawara, T. Nukiwa, Satoshi Oizumi et al.|Annals of Oncology|2015Cited by 111
Lung cancer prevention with (-)-epigallocatechin gallate using monitoring by heterogeneous nuclear ribonucleoprotein B1Nobukazu Fujimoto, H. Fujiki, Naoko Sueoka et al.|International Journal of Oncology|2002Cited by 38